Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms, Neoplasms

Breast Cancer Metastatic

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasm Female

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

HER2+ Breast Cancer

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

HER2-positive Breast Cancer

Estrogen Receptor-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms, Cardiotoxicity

Breast Neoplasms, Cardiotoxicity

Breast Neoplasms

HER2+ Early or Locally Advanced Breast Cancer

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Diseases, Breast Neoplasms

Breast Diseases, Breast Neoplasms

HER2-positive Breast Cancer

Clinical Trials

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

ROME

BiOnHER

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

HIST-RIC

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

VinCaT

FB-12

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

easy laugh

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

NeoPATH

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

HERMET

NeoTPPF

NSABP Biospecimen Discovery Project

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Pyramid

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

FAVOR

SOBER

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer